Krónikus C hepatitis isoprinosin kezelése (Multicentrikus, prospektív, placebo-kontrollos kettös-vak vizsgálat).

Translated title of the contribution: Isoprinosine therapy in chronic hepatitis C (multicenter placebo-controlled double-blind prospective study)

A. Pár, T. Beró, G. Brasch, A. Gógl, G. Kamarás, E. Méhesfalvi, Z. Ozsvár, M. Paál, I. Szipöcs, L. Telegdy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A placebo controlled clinical trial. Thirty two patients with chronic C hepatitis have been enrolled in a double blinded study to assess the therapeutic effect on an orally given antiviral-immunomodulatory drug, Isoprinosine. Seventeen patients were given Isoprinosine (3 g/day) and fifteen were on placebo. The treatment has been lasted for four months, when patients examined monthly. Clinical signs, liver function tests and side effects were evaluated. At the end of the trial, side effects and elevated serum alanine aminotransferase (ALT/GPT) levels occurred with higher frequency in Isoprinosine-treated patients. The results show that this antiviral drug has no beneficial effect in chronic C hepatitis.

Translated title of the contributionIsoprinosine therapy in chronic hepatitis C (multicenter placebo-controlled double-blind prospective study)
Original languageHungarian
Pages (from-to)1015-1019
Number of pages5
JournalOrvosi hetilap
Volume134
Issue number19
Publication statusPublished - May 9 1993

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Isoprinosine therapy in chronic hepatitis C (multicenter placebo-controlled double-blind prospective study)'. Together they form a unique fingerprint.

  • Cite this

    Pár, A., Beró, T., Brasch, G., Gógl, A., Kamarás, G., Méhesfalvi, E., Ozsvár, Z., Paál, M., Szipöcs, I., & Telegdy, L. (1993). Krónikus C hepatitis isoprinosin kezelése (Multicentrikus, prospektív, placebo-kontrollos kettös-vak vizsgálat). Orvosi hetilap, 134(19), 1015-1019.